- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Torrent Pharmaceuticals has reported its Q3 FY25 financial results, showing a 3% increase in revenue to ₹2,809 crore, alongside a 14% growth in net profit, which reached ₹503 crore. The firm maintains a strong gross margin of 76.0% and an operating EBITDA margin of 32.5%, reflecting solid operational performance.
In the domestic market, revenues surged by 12% to ₹1,581 crore, outperforming industry growth. However, Brazil's revenues dipped by 7% to ₹291 crore due to significant BRL depreciation. In Germany and the US, revenues slightly increased to ₹282 crore and declined to ₹271 crore, respectively. The USFDA recently issued an Establishment Inspection Report (EIR) for the Madhya Pradesh facility, with two ANDA approvals in Q3.
The underlying revenue growth for the quarter, adjusted for transitional impacts, stands at 7%, indicating a positive trajectory for the company, despite short-term challenges. Investors should watch the company closely as it navigates these dynamics.